acetazolamide has been researched along with Pulmonary Disease, Chronic Obstructive in 22 studies
Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)
Pulmonary Disease, Chronic Obstructive: A disease of chronic diffuse irreversible airflow obstruction. Subcategories of COPD include CHRONIC BRONCHITIS and PULMONARY EMPHYSEMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We searched Medline, EMBASE and CENTRAL from inception to March 2022 for randomised controlled trials comparing acetazolamide to placebo in patients with chronic obstructive pulmonary disease, obesity hypoventilation syndrome or obstructive sleep apnoea, hospitalised with acute respiratory deterioration complicated by metabolic alkalosis." | 9.41 | Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review. ( Bemand, TJ; Chatoor, R; Delaney, A; Natale, P; Strippoli, G, 2023) |
| "The purpose of the study was to evaluate the effectiveness of short-term treatment with acetazolamide for combined respiratory failure and metabolic alkalosis." | 9.17 | Acetazolamide improves oxygenation in patients with respiratory failure and metabolic alkalosis. ( Bruun Wyller, T; Frostad, A; Gulsvik, R; Hansen, G; Holø, L; Humerfelt, S; Lejlic, V; Saure, EW; Skjørten, I; Undhjem, K, 2013) |
| "To evaluate the effects of a single daily dose of acetazolamide (ACET) on metabolic alkalosis and respiratory parameters in weaning chronic obstructive pulmonary disease (COPD) patients from invasive mechanical ventilation." | 7.76 | Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. ( Fagon, JY; Faisy, C; Mokline, A; Sanchez, O; Tadié, JM, 2010) |
| "Eleven AECOPD patients, with hypercapnic respiratory failure and MA following NIV, were treated with ACET 500 mg for two consecutive days and compared to a matched control group." | 5.43 | Effect of acetazolamide on post-NIV metabolic alkalosis in acute exacerbated COPD patients. ( Alessandrini, G; Bonini, M; Borgognoni, L; Ferrazza, AM; Fontana, V; Internullo, M; Marinelli, P; Palange, P; Santinelli, S; Sardo, L, 2016) |
| "We searched Medline, EMBASE and CENTRAL from inception to March 2022 for randomised controlled trials comparing acetazolamide to placebo in patients with chronic obstructive pulmonary disease, obesity hypoventilation syndrome or obstructive sleep apnoea, hospitalised with acute respiratory deterioration complicated by metabolic alkalosis." | 5.41 | Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review. ( Bemand, TJ; Chatoor, R; Delaney, A; Natale, P; Strippoli, G, 2023) |
| "The purpose of the study was to evaluate the effectiveness of short-term treatment with acetazolamide for combined respiratory failure and metabolic alkalosis." | 5.17 | Acetazolamide improves oxygenation in patients with respiratory failure and metabolic alkalosis. ( Bruun Wyller, T; Frostad, A; Gulsvik, R; Hansen, G; Holø, L; Humerfelt, S; Lejlic, V; Saure, EW; Skjørten, I; Undhjem, K, 2013) |
| "This study identified several covariates that influenced acetazolamide pharmacodynamics and could allow a better individualization of acetazolamide dosing when treating COPD patients with metabolic alkalosis." | 3.77 | Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients. ( Faisy, C; Heming, N; Urien, S, 2011) |
| "To evaluate the effects of a single daily dose of acetazolamide (ACET) on metabolic alkalosis and respiratory parameters in weaning chronic obstructive pulmonary disease (COPD) patients from invasive mechanical ventilation." | 3.76 | Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation. ( Fagon, JY; Faisy, C; Mokline, A; Sanchez, O; Tadié, JM, 2010) |
| "Among patients with MA and COPD or OHS, early treatment with ACTZ did not shorten significantly the duration of MV compared with placebo." | 2.84 | Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial. ( Heras la Calle, G; Martín Delgado, MC; Mas Serra, A; Morán Chorro, I; Raurich Puigdevall, JM; Rialp Cervera, G; Vallverdú Perapoch, I, 2017) |
| "Acetazolamide has been used for decades as a respiratory stimulant for patients with chronic obstructive pulmonary disease (COPD) and metabolic alkalosis, but no large randomized placebo-controlled trial is available to confirm this approach." | 2.82 | Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial. ( Bornstain, C; Clavel, M; Djibre, M; Duguet, A; Esvan, M; Faisy, C; Gacouin, A; Gibot, S; Heming, N; Katsahian, S; Lerolle, N; Meziani, F; Planquette, B; Rabbat, A; Ricard, JD; Ricome, JL; Sanchez, O; Schneider, F; Urien, S, 2016) |
| "Acetazolamide is a carbonic anhydrase (CA) inhibitor sometimes used as a respiratory stimulant for patients with chronic obstructive pulmonary disease (COPD) with the goal of improving oxygenation, reducing carbon dioxide retention, and aiding liberation from mechanical ventilation and/or attempting to correct a metabolic alkalosis." | 2.55 | Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons. ( Adamson, R; Swenson, ER, 2017) |
| "Patients with chronic obstructive pulmonary disease (COPD) are affected by episodes of respiratory exacerbations, some of which can be severe and may necessitate respiratory support." | 2.48 | Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit? ( Faisy, C; Heming, N; Urien, S, 2012) |
| "High-altitude pulmonary edema is a non-cardiac edema that often precedes acute mountain sickness." | 2.42 | [Visiting high altitudes--healthy persons and patients with risk diseases]. ( Fischer, R, 2004) |
| "Acetazolamide can produce a small increase in arterial PO2 and fall in PCO2." | 2.41 | Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease. ( Greenstone, M; Jones, PW, 2001) |
| "Eleven AECOPD patients, with hypercapnic respiratory failure and MA following NIV, were treated with ACET 500 mg for two consecutive days and compared to a matched control group." | 1.43 | Effect of acetazolamide on post-NIV metabolic alkalosis in acute exacerbated COPD patients. ( Alessandrini, G; Bonini, M; Borgognoni, L; Ferrazza, AM; Fontana, V; Internullo, M; Marinelli, P; Palange, P; Santinelli, S; Sardo, L, 2016) |
| "Acetazolamide is one of the treatments used to reverse metabolic alkalosis." | 1.40 | Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients. ( Clavel, M; Faisy, C; Fulda, V; Gacouin, A; Heming, N; Meziani, F; Planquette, B; Urien, S, 2014) |
| "Normocapnic and chronic hypercapnic COPD patients have the same ventilatory and cerebrovascular carbon dioxide responsiveness irrespective of induced metabolic state." | 1.31 | Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD. ( Colier, WN; Folgering, H; Oeseburg, B; van de Ven, MJ; van der Sluijs, MC; Vis, P, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (31.82) | 29.6817 |
| 2010's | 13 (59.09) | 24.3611 |
| 2020's | 2 (9.09) | 2.80 |
| Authors | Studies |
|---|---|
| Bemand, TJ | 1 |
| Chatoor, R | 1 |
| Natale, P | 1 |
| Strippoli, G | 1 |
| Delaney, A | 1 |
| Bloch, KE | 1 |
| Sooronbaev, TM | 1 |
| Ulrich, S | 1 |
| Lichtblau, M | 1 |
| Furian, M | 1 |
| Adamson, R | 1 |
| Swenson, ER | 1 |
| Gulsvik, R | 1 |
| Skjørten, I | 1 |
| Undhjem, K | 1 |
| Holø, L | 1 |
| Frostad, A | 1 |
| Saure, EW | 1 |
| Lejlic, V | 1 |
| Humerfelt, S | 1 |
| Hansen, G | 1 |
| Bruun Wyller, T | 1 |
| Heming, N | 5 |
| Urien, S | 4 |
| Fulda, V | 1 |
| Meziani, F | 2 |
| Gacouin, A | 2 |
| Clavel, M | 2 |
| Planquette, B | 2 |
| Faisy, C | 6 |
| Fontana, V | 1 |
| Santinelli, S | 1 |
| Internullo, M | 1 |
| Marinelli, P | 1 |
| Sardo, L | 1 |
| Alessandrini, G | 1 |
| Borgognoni, L | 1 |
| Ferrazza, AM | 1 |
| Bonini, M | 1 |
| Palange, P | 1 |
| Bornstain, C | 1 |
| Schneider, F | 1 |
| Duguet, A | 1 |
| Gibot, S | 1 |
| Lerolle, N | 1 |
| Ricard, JD | 1 |
| Sanchez, O | 2 |
| Djibre, M | 1 |
| Ricome, JL | 1 |
| Rabbat, A | 1 |
| Esvan, M | 1 |
| Katsahian, S | 1 |
| Contou, D | 1 |
| de Prost, N | 1 |
| Mekontso Dessap, A | 1 |
| Mishra, S | 1 |
| Azim, A | 1 |
| Baronia, A | 1 |
| Rialp Cervera, G | 1 |
| Raurich Puigdevall, JM | 1 |
| Morán Chorro, I | 1 |
| Martín Delgado, MC | 1 |
| Heras la Calle, G | 1 |
| Mas Serra, A | 1 |
| Vallverdú Perapoch, I | 1 |
| Mokline, A | 1 |
| Tadié, JM | 1 |
| Fagon, JY | 1 |
| Prieto de Paula, JM | 1 |
| Franco Hidalgo, S | 1 |
| Borge Gallardo, L | 1 |
| Mayor Toranzo, E | 1 |
| Wagenaar, M | 2 |
| Vos, PJ | 1 |
| Heijdra, YF | 1 |
| Teppema, LJ | 1 |
| Folgering, HT | 1 |
| Vos, P | 1 |
| Heijdra, Y | 1 |
| Teppema, L | 1 |
| Folgering, H | 2 |
| Cole, RP | 1 |
| Bales, MJ | 1 |
| Timpe, EM | 1 |
| Fischer, R | 1 |
| Jones, PW | 1 |
| Greenstone, M | 1 |
| van de Ven, MJ | 1 |
| Colier, WN | 1 |
| van der Sluijs, MC | 1 |
| Oeseburg, B | 1 |
| Vis, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Acetazolamide for Respiratory Failure in Combination With Metabolic Alkalosis[NCT00222534] | Phase 4 | 70 participants (Actual) | Interventional | 2002-01-31 | Completed | ||
| A Randomized Trial to Evaluate Effectiveness of Acetazolamide in COPD Patients Developing Metabolic Alkalosis During Invasive Mechanical Ventilation[NCT01627639] | Phase 4 | 380 participants (Actual) | Interventional | 2011-10-31 | Completed | ||
| Effects of Acetazolamide on the Duration of Mechanical Ventilation in Patients With Metabolic Alkalosis. Phase III Multicenter Double-blinded Clinical Trial.[NCT01499485] | Phase 3 | 140 participants (Actual) | Interventional | 2011-11-30 | Completed | ||
| Brain During Effort : Effects of Hypoxia With Respiratory Patients[NCT02854280] | 33 participants (Actual) | Interventional | 2013-06-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for acetazolamide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Acetazolamide for metabolic alkalosis complicating respiratory failure with chronic obstructive pulmonary disease or obesity hypoventilation syndrome: a systematic review.
Topics: Acetazolamide; Alkalosis; Humans; Obesity Hypoventilation Syndrome; Pulmonary Disease, Chronic Obstr | 2023 |
Acetazolamide Use in Severe Chronic Obstructive Pulmonary Disease. Pros and Cons.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Endothelium, Vascular; Erythrocytes; Humans; Kidney; P | 2017 |
Acetazolamide: a second wind for a respiratory stimulant in the intensive care unit?
Topics: Acetazolamide; Alkalosis; Carbonic Anhydrase Inhibitors; Humans; Intensive Care Units; Pulmonary Dis | 2012 |
Respiratory stimulant use in chronic obstructive pulmonary disease.
Topics: Acetazolamide; Humans; Medroxyprogesterone Acetate; Pulmonary Disease, Chronic Obstructive; Randomiz | 2004 |
[Visiting high altitudes--healthy persons and patients with risk diseases].
Topics: Acclimatization; Acetazolamide; Acute Disease; Altitude; Altitude Sickness; Anti-Inflammatory Agents | 2004 |
Carbonic anhydrase inhibitors for hypercapnic ventilatory failure in chronic obstructive pulmonary disease.
Topics: Acetazolamide; Carbonic Anhydrase Inhibitors; Clinical Trials as Topic; Female; Humans; Hypercapnia; | 2001 |
5 trials available for acetazolamide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Acetazolamide improves oxygenation in patients with respiratory failure and metabolic alkalosis.
Topics: Acetazolamide; Aged; Aged, 80 and over; Alkalosis; Carbon Dioxide; Carbonic Anhydrase Inhibitors; Do | 2013 |
Effect of Acetazolamide vs Placebo on Duration of Invasive Mechanical Ventilation Among Patients With Chronic Obstructive Pulmonary Disease: A Randomized Clinical Trial.
Topics: Acetazolamide; Aged; Alkalosis, Respiratory; Bicarbonates; Carbon Dioxide; Carbonic Anhydrase Inhibi | 2016 |
Effects of early administration of acetazolamide on the duration of mechanical ventilation in patients with chronic obstructive pulmonary disease or obesity-hypoventilation syndrome with metabolic alkalosis. A randomized trial.
Topics: Acetazolamide; Acidosis; Aged; Bicarbonates; Blood Gas Analysis; Double-Blind Method; Female; Follow | 2017 |
Combined treatment with acetazolamide and medroxyprogesterone in chronic obstructive pulmonary disease patients.
Topics: Acetazolamide; Aged; Carbon Dioxide; Carbonic Anhydrase Inhibitors; Double-Blind Method; Drug Therap | 2002 |
Comparison of acetazolamide and medroxyprogesterone as respiratory stimulants in hypercapnic patients with COPD.
Topics: Acetazolamide; Aged; Cross-Over Studies; Double-Blind Method; Female; Humans; Hypercapnia; Hypoxia; | 2003 |
11 other studies available for acetazolamide and Pulmonary Disease, Chronic Obstructive
| Article | Year |
|---|---|
Counseling Patients with Chronic Obstructive Pulmonary Disease Traveling to High Altitude.
Topics: Acetazolamide; Altitude; Counseling; Dyspnea; Humans; Hypoxia; Pulmonary Disease, Chronic Obstructiv | 2023 |
Population pharmacodynamic modeling and simulation of the respiratory effect of acetazolamide in decompensated COPD patients.
Topics: Acetazolamide; Computer Simulation; Dose-Response Relationship, Drug; Humans; Models, Biological; Pu | 2014 |
Effect of acetazolamide on post-NIV metabolic alkalosis in acute exacerbated COPD patients.
Topics: Acetazolamide; Acid-Base Equilibrium; Acute Disease; Aged; Aged, 80 and over; Alkalosis; Carbonic An | 2016 |
Acetazolamide and Invasive Mechanical Ventilation for Patients With COPD.
Topics: Acetazolamide; Alkalosis, Respiratory; Carbonic Anhydrase Inhibitors; Female; Humans; Male; Pulmonar | 2016 |
Acetazolamide and Invasive Mechanical Ventilation for Patients With COPD.
Topics: Acetazolamide; Alkalosis, Respiratory; Carbonic Anhydrase Inhibitors; Female; Humans; Male; Pulmonar | 2016 |
Acetazolamide and Invasive Mechanical Ventilation for Patients With COPD--Reply.
Topics: Acetazolamide; Alkalosis, Respiratory; Carbonic Anhydrase Inhibitors; Female; Humans; Male; Pulmonar | 2016 |
Effectiveness of acetazolamide for reversal of metabolic alkalosis in weaning COPD patients from mechanical ventilation.
Topics: Acetazolamide; Aged; Alkalosis; Bicarbonates; Carbonic Anhydrase Inhibitors; Case-Control Studies; F | 2010 |
Population pharmacodynamic model of bicarbonate response to acetazolamide in mechanically ventilated chronic obstructive pulmonary disease patients.
Topics: Acetazolamide; Adult; Aged; Aged, 80 and over; Alkalosis; Bicarbonates; Carbonic Anhydrase Inhibitor | 2011 |
The importance of identifying the association between metabolic alkalosis and respiratory acidosis.
Topics: Acetazolamide; Acidosis, Respiratory; Alkalosis; Bicarbonates; Furosemide; Humans; Obesity Hypoventi | 2012 |
Carbon dioxide production during acetazolamide and medroxyprogesterone treatment.
Topics: Acetazolamide; Carbon Dioxide; Carbonic Anhydrase Inhibitors; Drug Therapy, Combination; Humans; Hyp | 2003 |
Effects of acetazolamide and furosemide on ventilation and cerebral blood volume in normocapnic and hypercapnic patients with COPD.
Topics: Acetazolamide; Administration, Oral; Alkalosis; Blood Volume; Carbon Dioxide; Cerebrovascular Circul | 2002 |